Month: November 2014

After Harvoni: What’s Still Left to Improve (Besides the Price Tag)?

Posted on by — No Comments ↓

SVR rates in recent DAA combination trials are really impressive.  Hardly a month goes by without yet another trial showing excellent efficacy in populations so far considered ‘difficult to treat’, like cirrhotics or post-liver transplant patients on immunosuppressive therapies.  This begs the question: is there still room for improvement?  Why Continue reading After Harvoni: What’s Still Left to Improve (Besides the Price Tag)?→

Two New Approaches For Dealing with Sepsis / Toxemia

Posted on by — No Comments ↓

There is hardly an indication which has accumulated more failed clinical trials than the sepsis area.  Called first bacteremia, later sepsis, sepsis syndrome or septic shock, there have been numerous attempts to influence the cascade of events that eventually lead to MSOF and death.  While it is convenient to think Continue reading Two New Approaches For Dealing with Sepsis / Toxemia→

2014: The Year That Changed The Landscape of HCV Therapy

Posted on by — No Comments ↓

It was déjà vu all over again, albeit compressed in time: when the race started to replace PegIFN+RBV for the treatment of HCV infection, the learnings from HIV drug development and the lessons with HAART provided an excellent template for quick and efficient development. There was early consensus that a search Continue reading 2014: The Year That Changed The Landscape of HCV Therapy→